128 related articles for article (PubMed ID: 9544934)
21. Multiplex PCR to identify macrolide resistance determinants in Mannheimia haemolytica and Pasteurella multocida.
Rose S; Desmolaize B; Jaju P; Wilhelm C; Warrass R; Douthwaite S
Antimicrob Agents Chemother; 2012 Jul; 56(7):3664-9. PubMed ID: 22564832
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of tildipirosin in porcine plasma, lung tissue, and bronchial fluid and effects of test conditions on in vitro activity against reference strains and field isolates of Actinobacillus pleuropneumoniae.
Rose M; Menge M; Bohland C; Zschiesche E; Wilhelm C; Kilp S; Metz W; Allan M; Röpke R; Nürnberger M
J Vet Pharmacol Ther; 2013 Apr; 36(2):140-53. PubMed ID: 22500881
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic/pharmacodynamic integration and modelling of florfenicol for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.
Dorey L; Pelligand L; Cheng Z; Lees P
PLoS One; 2017; 12(5):e0177568. PubMed ID: 28552968
[TBL] [Abstract][Full Text] [Related]
24. Factors influencing the potency of marbofloxacin for pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.
Dorey L; Hobson S; Lees P
Res Vet Sci; 2017 Apr; 111():93-98. PubMed ID: 28113129
[TBL] [Abstract][Full Text] [Related]
25. Prediction of marbofloxacin dosage for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida by pharmacokinetic/pharmacodynamic modelling.
Dorey L; Pelligand L; Lees P
BMC Vet Res; 2017 Jul; 13(1):209. PubMed ID: 28666426
[TBL] [Abstract][Full Text] [Related]
26. Comparison between the minimal inhibitory concentration of tilmicosin and oxytetracycline for bovine pneumonic Pasteurella haemolytica isolates.
Hartman EG; Geryl J
Vet Q; 1993 Dec; 15(4):184. PubMed ID: 8122359
[TBL] [Abstract][Full Text] [Related]
27. Activity of florfenicol for Actinobacillus pleuropneumoniae and Pasteurella multocida using standardised versus non-standardised methodology.
Dorey L; Hobson S; Lees P
Vet J; 2016 Dec; 218():65-70. PubMed ID: 27938711
[TBL] [Abstract][Full Text] [Related]
28. Application of enrofloxacin and orbifloxacin disks approved in Japan for susceptibility testing of representative veterinary respiratory pathogens.
Harada K; Usui M; Asai T
J Vet Med Sci; 2014 Oct; 76(10):1427-30. PubMed ID: 25008965
[TBL] [Abstract][Full Text] [Related]
29. Comparison of standardised versus non-standardised methods for testing the in vitro potency of oxytetracycline against Mannheimia haemolytica and Pasteurella multocida.
Lees P; Illambas J; Pelligand L; Toutain PL
Vet J; 2016 Dec; 218():60-64. PubMed ID: 27938710
[TBL] [Abstract][Full Text] [Related]
30. Potency of marbofloxacin for pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida: Comparison of growth media.
Dorey L; Hobson S; Lees P
Res Vet Sci; 2017 Apr; 111():43-48. PubMed ID: 27940285
[TBL] [Abstract][Full Text] [Related]
31. A ten-year (2000-2009) study of antimicrobial susceptibility of bacteria that cause bovine respiratory disease complex--Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni--in the United States and Canada.
Portis E; Lindeman C; Johansen L; Stoltman G
J Vet Diagn Invest; 2012 Sep; 24(5):932-44. PubMed ID: 22914822
[TBL] [Abstract][Full Text] [Related]
32. Clinical field trials with tilmicosin phosphate in feed for the control of naturally acquired pneumonia caused by Actinobacillus pleuropneumoniae and Pasteurella multocida in swine.
Moore GM; Basson RP; Tonkinson LV
Am J Vet Res; 1996 Feb; 57(2):224-8. PubMed ID: 8633813
[TBL] [Abstract][Full Text] [Related]
33. Antimicrobial susceptibility of Actinobacillus pleuropneumoniae, Pasteurella multocida and Salmonella choleraesuis isolates from pigs.
Raemdonck DL; Tanner AC; Tolling ST; Michener SL
Vet Rec; 1994 Jan; 134(1):5-7. PubMed ID: 8128570
[TBL] [Abstract][Full Text] [Related]
34. New interpretive criteria for danofloxacin antibacterial susceptibility testing against Mannheimia haemolytica and Pasteurella multocida associated with bovine respiratory disease.
Sweeney MT; Papich MG; Watts JL
J Vet Diagn Invest; 2017 Mar; 29(2):224-227. PubMed ID: 28064562
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline for the calf pathogens Mannheimia haemolytica and Pasteurella multocida.
Lees P; Potter T; Pelligand L; Toutain PL
J Vet Pharmacol Ther; 2018 Feb; 41(1):28-38. PubMed ID: 28736817
[TBL] [Abstract][Full Text] [Related]
36. Tilmicosin enteric granules and premix to pigs: Antimicrobial susceptibility testing and comparative pharmacokinetics.
Xiong J; Zhu Q; Zhao Y; Yang S; Cao J; Qiu Y
J Vet Pharmacol Ther; 2019 May; 42(3):336-345. PubMed ID: 30801755
[TBL] [Abstract][Full Text] [Related]
37. A large potentiation effect of serum on the in vitro potency of tulathromycin against Mannheimia haemolytica and Pasteurella multocida.
Lees P; Illambas J; Potter TJ; Pelligand L; Rycroft A; Toutain PL
J Vet Pharmacol Ther; 2017 Oct; 40(5):419-428. PubMed ID: 27891615
[TBL] [Abstract][Full Text] [Related]
38. In vitro susceptibility of porcine respiratory pathogens to tilmicosin.
DeRosa DC; Veenhuizen MF; Bade DJ; Shryock TR
J Vet Diagn Invest; 2000 Nov; 12(6):541-6. PubMed ID: 11108454
[TBL] [Abstract][Full Text] [Related]
39. Increased MICs of gamithromycin and tildipirosin in the presence of the genes erm(42) and msr(E)-mph(E) for bovine Pasteurella multocida and Mannheimia haemolytica.
Michael GB; Eidam C; Kadlec K; Meyer K; Sweeney MT; Murray RW; Watts JL; Schwarz S
J Antimicrob Chemother; 2012 Jun; 67(6):1555-7. PubMed ID: 22398653
[No Abstract] [Full Text] [Related]
40. In vitro activities of spectinomycin and comparator agents against Pasteurella multocida and Mannheimia haemolytica from respiratory tract infections of cattle.
Schwarz S; Kehrenberg C; Salmon SA; Watts JL
J Antimicrob Chemother; 2004 Feb; 53(2):379-82. PubMed ID: 14729757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
